CN103230552B - Traditional Chinese medicine for treating diabetes mellitus - Google Patents
Traditional Chinese medicine for treating diabetes mellitus Download PDFInfo
- Publication number
- CN103230552B CN103230552B CN201310163090.1A CN201310163090A CN103230552B CN 103230552 B CN103230552 B CN 103230552B CN 201310163090 A CN201310163090 A CN 201310163090A CN 103230552 B CN103230552 B CN 103230552B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- diabetes mellitus
- group
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 23
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 20
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims description 34
- 244000025254 Cannabis sativa Species 0.000 claims description 15
- 241000219780 Pueraria Species 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 abstract description 27
- 239000008280 blood Substances 0.000 abstract description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 20
- 239000008103 glucose Substances 0.000 abstract description 20
- 241000700159 Rattus Species 0.000 abstract description 18
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract description 14
- 239000009636 Huang Qi Substances 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 11
- 229960004329 metformin hydrochloride Drugs 0.000 abstract description 10
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract description 10
- 230000037356 lipid metabolism Effects 0.000 abstract description 7
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000006870 function Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 235000009917 Crataegus X brevipes Nutrition 0.000 abstract 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 abstract 1
- 235000009685 Crataegus X maligna Nutrition 0.000 abstract 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 abstract 1
- 235000009486 Crataegus bullatus Nutrition 0.000 abstract 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 abstract 1
- 235000009682 Crataegus limnophila Nutrition 0.000 abstract 1
- 235000004423 Crataegus monogyna Nutrition 0.000 abstract 1
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 235000002313 Crataegus paludosa Nutrition 0.000 abstract 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 235000001727 glucose Nutrition 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 10
- 108010054147 Hemoglobins Proteins 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000011552 rat model Methods 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000003304 gavage Methods 0.000 description 7
- 229940080268 lotensin Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108090000244 Rat Proteins Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- -1 1 time Substances 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 229940097420 Diuretic Drugs 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000001084 renoprotective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine for treating diabetes mellitus. The traditional Chinese medicine is prepared from the following raw materials in parts by weight: 50-100 parts of salvia miltiorrhiza, 50-100 parts of radix astragali, 30-60 parts of herba spirodelae, 10-40 parts of mulberry twig, 20-50 parts of semen coicis, 20-50 parts of kudzuvine root and 10-40 parts of hawthorn. Pharmacological experiments prove that the traditional Chinese medicine has the functions of obviously reducing fasting blood glucose and glycosylated haemoglobin of experimental rats with type 2 diabetes mellitus, reducing proteinuria of experimental rats with diabetic nephropathy and simultaneously regulating lipid metabolism of experimental rats with diabetic nephropathy. Clinical tests show that the traditional Chinese medicine has a total effective rate of 76.6% in treating patients with type 2 diabetes mellitus, does not have significant difference from metformin hydrochloride tablet control groups, but is superior to metformin hydrochloride tablets in improving clinical symptoms of type 2 diabetes mellitus and regulating lipid metabolism.
Description
Technical field
The present invention relates to a kind of Chinese medicine, relate to specifically a kind of Chinese medicine for the treatment of diabetes.
Background technology
At present, in clinical used hypoglycemic medicine, various Western medicine have certain limitation and very serious untoward reaction, as cause hypoglycemia, lactic acidosis etc., and Chinese medicine lack curative effect certainly, all easy antihypelipidemic preparations of reception of clinician and patient.Go back so far neither one medicine and can thoroughly cure diabetes, Western medicine also just can be controlled blood glucose, and by contrast, Chinese medicine has the advantage of himself, and has good development prospect.Someone thinks, the blood sugar lowering mechanism of Chinese medicine with regulate body immunologic function, to improve insulin relevant with its receptors bind, and strengthens emiocytosis insulin, this may be that Chinese medicine be treated diabetes by raising immunity of organisms and opened up a new way.
Diabetic nephropathy adopts antihypertensive drug therapy conventionally, if angiotensin converting enzyme inhibitor or Angiotensin Ⅱ receptor antagonist are often choice drug, often need to combine other depressor as calcium antagonist, diuretic, beta-blocker, methyldopa, clonidine etc.But these Western medicine effects can not be lasting, need Long-term taking medicine, and side effect is large.Due to diabetic nephropathy patient internal organs weakness, therefore traditional Chinese medical science employing righting is main, according to patient's medicine typing, adopts the means such as spleen invigorating, kidney tonifying, gives righting to get rid of evils, and has obtained good therapeutic effect.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine for the treatment of diabetes.
Above-mentioned purpose is achieved through the following technical solutions:
Treat a Chinese medicine for diabetes, described Chinese medicine is made up of the raw material of following weight proportioning:
10 ~ 40 parts of 30 ~ 60 parts of Ramulus Moris of 50 ~ 100 parts of Herba Spirodelae grass of 50 ~ 100 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
10 ~ 40 parts of 20 ~ 50 portions of Fructus Crataegis of 20 ~ 50 parts of Radix Puerariaes of Semen Coicis.
Preferably, the weight proportion of described raw material is:
20 ~ 30 parts of 40 ~ 50 parts of Ramulus Moris of 60 ~ 80 parts of Herba Spirodelae grass of 60 ~ 80 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
20 ~ 30 parts of 30 ~ 40 portions of Fructus Crataegis of 30 ~ 40 parts of Radix Puerariaes of Semen Coicis.
Best, the weight proportion of described raw material is:
25 parts of 45 parts of Ramulus Moris of 70 parts of Herba Spirodelae grass of 70 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
25 parts of 35 portions of Fructus Crataegis of 35 parts of Radix Puerariaes of Semen Coicis.
Described Chinese medicine is except above-mentioned raw materials, can also comprise adjuvant, described adjuvant can be one or more combination of conventional adjuvant in these pharmaceutical preparatioies such as sucrose, starch, dextrin, magnesium stearate, sorbitol, mannitol, lactose, microcrystalline Cellulose, micropowder silica gel, carboxymethyl cellulose, water, specifically select any or which plant adjuvant and should determine according to the required dosage form of making.Be the technology that those skilled in the art can grasp owing to need to select suitable adjuvant according to dosage form, therefore the needed adjuvant of preparation medicine of the present invention do not brought in the claimed scope of patent.
Described Chinese medicine can be any dosage form that is suitable for clinical use, for example: decoction, tablet, granule, capsule, pill, unguentum, mixture, syrup etc.Described raw material is made suitable dosage form after can pulverizing, also can after extracting, refine, concentrating, make again suitable dosage form, for example raw material can be boiled into decoction, also after can all pulverizing, add suitable adjuvant to make tablet, powder, granule, capsule, pill, or after raw material is all extracted, add again suitable adjuvant to make tablet, granule, capsule, unguentum, mixture, syrup, can also will after the pulverizing of raw material part, extracting section, add again suitable adjuvant to make tablet, granule, capsule etc.Extracting method can adopt decocting conventional in Chinese drug preparation to extract or ethanol reflux extraction.
The present invention is taking benefiting QI for activating blood circulation yin nourishing as the principles of formulating prescriptions.Radix Salviae Miltiorrhizae invigorating the spleen and replenishing QI, promoting the production of body fluid to quench thirst in side, reuse as monarch, and Radix Astragali benefiting QI for strengthening the superficies, arresting sweating are admittedly de-, are ministerial drug, and the merit that the existing damp eliminating of Herba Spirodelae grass is promoted the production of body fluid also has the effect of heat extraction removing heat from blood; Ramulus Mori has the effect of the diuretic of promoting the production of body fluid, for quenching one's thirst; Semen Coicis slightly sweet flavor is cool in nature, has the function of spleen invigorating eliminating dampness by diuresis, activating blood and promoting diuresis; Radix Puerariae relieving muscles diaphoresis, Fructus Crataegi is nourshing Yin and drynsessmoistening prescription, and the above five tastes and Radix Salviae Miltiorrhizae, Radix Astragali gas the moon of tonifying the lung spleen kidney altogether, makes the defeated cloth of body fluid reasonable, altogether for assistant makes, full side's reinforcement and elimination in combination, righting is got rid of evils, and coordinates internal organs negative and positive, and blood stasis poison heresy is gone to the greatest extent.
Pharmacological evaluation proves, the present invention has the effect of remarkable reduction rat model of type 2 diabetes mellitus fasting glucose, glycolated hemoglobin.Have the albuminuretic effect of the diabetic nephropathy rats of reduction, have the effect that regulates diabetic nephropathy rats lipid metabolism simultaneously, prompting the present invention has the effect of protection kidney.Clinical trial shows, the present invention is 76.6% to the treatment total effective rate of 2 phase diabeticss, with metformin hydrochloride tablet matched group there was no significant difference, but is better than metformin hydrochloride tablet improving aspect the clinical symptoms of 2 phase diabetes and adjusting lipid metabolism.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in detail.
Embodiment 1
Treat a Chinese medicine for diabetes, it is made up of the raw material of following weight proportioning:
Radix Salviae Miltiorrhizae 50Kg Radix Astragali 50Kg Herba Spirodelae grass 30Kg Ramulus Mori 10Kg
Semen Coicis 20Kg Radix Puerariae 20Kg Fructus Crataegi 10Kg.
Preparation method is: Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into coarse powder and add by weight the ethanol that 6 times of weight concentrations are 80%, reflux, extract, 3 times, each 1 hour, filter, it is 1.08 extractum that merging filtrate concentrating under reduced pressure become relative density, filtering residue adds by weight the decocting of 6 times to boil 3 times together with the Radix Astragali, Herba Spirodelae grass, Ramulus Mori, Semen Coicis, each 1 hour, filter, filtrate and above-mentioned extractum merge, be condensed into relative density and be 1.25 extractum, add the agent of mannitol granulation.
Instructions of taking: bfore meals, every day three times, each one bag (each serving with being equivalent to raw medicinal herbs 63g).
Embodiment 2
Treat a Chinese medicine for diabetes, it is made up of the raw material of following weight proportioning:
Radix Salviae Miltiorrhizae 100Kg Radix Astragali 100Kg Herba Spirodelae grass 60Kg Ramulus Mori 40Kg
Semen Coicis 50Kg Radix Puerariae 50Kg Fructus Crataegi 40Kg.
Preparation method is: Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into coarse powder and add by weight the ethanol that 12 times of weight concentrations are 50%, reflux, extract, 1 time, extract 3 hours, filter, it is 1.15 extractum that merging filtrate concentrating under reduced pressure become relative density, filtering residue adds by weight the decocting of 15 times to boil 1 time together with the Radix Astragali, Herba Spirodelae grass, Ramulus Mori, Semen Coicis, decoct 3 hours, filter, filtrate and above-mentioned extractum merge, be condensed into relative density and be 1.40 extractum, add microcrystalline Cellulose and starch to be pressed into tablet.
Instructions of taking: bfore meals, every day three times, each 3 (being equivalent to raw medicinal herbs 46g).
Embodiment 3
Treat a Chinese medicine for diabetes, it is made up of the raw material of following weight proportioning:
Radix Salviae Miltiorrhizae 70Kg Radix Astragali 70Kg Herba Spirodelae grass 45Kg Ramulus Mori 25Kg
Semen Coicis 35Kg Radix Puerariae 35Kg Fructus Crataegi 25Kg.
Preparation method is:
Radix Salviae Miltiorrhizae, powder of Radix Puerariae are broken into coarse powder and add by weight the ethanol that 8 times of weight concentrations are 60%, reflux, extract, 2 times, each 2 hours, filters, it is 1.1 extractum that merging filtrate concentrating under reduced pressure become relative density, filtering residue adds by weight the decocting of 10 times to boil 1 time together with the Radix Astragali, Herba Spirodelae grass, Ramulus Mori, Semen Coicis, and decocting time is 3 hours, filters, filtrate and above-mentioned extractum merge, be condensed into relative density and be 1.32 extractum, add appropriate amount of starch granulation, with making capsule after capsule-filling.
Instructions of taking: bfore meals, every day three times, each 3 (being equivalent to raw medicinal herbs 50g).
Embodiment 4
Treat a Chinese medicine for diabetes, it is made up of the raw material of following weight proportioning:
Radix Salviae Miltiorrhizae 60g Radix Astragali 80g Herba Spirodelae grass 50g Ramulus Mori 30g
Semen Coicis 30g Radix Puerariae 40g Fructus Crataegi 20g.
Preparation method is: decoct with water three times, each 20 minutes, make decoction.
Instructions of taking: bfore meals, every day three times (each serving with being equivalent to raw medicinal herbs 45g).
Embodiment 5
Treat a Chinese medicine for diabetes, it is made up of the raw material of following weight proportioning:
Radix Salviae Miltiorrhizae 80g Radix Astragali 60g Herba Spirodelae grass 40g Ramulus Mori 20g
Semen Coicis 40g Radix Puerariae 30g Fructus Crataegi 30g.
Preparation method is: decoct with water three times, each 15 minutes, make decoction.
Instructions of taking: bfore meals, every day three times (each serving with being equivalent to raw medicinal herbs 38g).
The impact of embodiment 6 the present invention on rat model of type 2 diabetes mellitus fasting glucose and glycolated hemoglobin
This experiment, taking the rat model of type 2 diabetes mellitus due to streptozotocin as animal model, is investigated pharmacological action of the present invention.
1, materials and methods
1) 1. animal of material: SD rat, healthy male, body weight 160 ~ 210g, provided by pharmaceutical college of Wuhan University pharmacological evaluation chamber, 2. medicine and reagent: when the drug test of the embodiment of the present invention, water is mixed with the solution of desired concn, metformin hydrochloride tablet is purchased from Qilu Pharmaceutical Co., Ltd., is ground into fine powder water and is mixed with the solution of desired concn when test.Glucose assays test kit and glycolated hemoglobin are measured test kit and are provided by Beijing Zhong Sheng biotechnology company.
2) 1. method divides into rat model of type 2 diabetes mellitus Normal group, model control group, metformin group, 1 group of embodiment, 2 groups of embodiment, 3 groups of embodiment at random.2. medication: Normal group: gavage distilled water; Model control group: gavage distilled water; Metformin group: gavage metformin hydrochloride, every day, dosage was 250mg/Kg; 1,2,3 groups of embodiment: every day, dosage was 6g crude drug/Kg.Every group every day gavage once, continuous 30 days.
3) statistical method experimental data with mean ± standard deviation (
) represent, adopt spss13.0 statistical software, between organizing relatively, significance level is taking 0.05 and 0.01 as standard for one factor analysis of variance.
2, result
1) rat model of type 2 diabetes mellitus copies after successfully grouping, through 4 weeks Drug therapys, model group fasting glucose compared with normal matched group obviously raises (P<0.01), metformin group, 1 group of embodiment, 2 groups of embodiment, 3 groups of fasting glucose compared with normal matched groups of embodiment significantly decline (P<0.01); Model group glycolated hemoglobin and Normal group significantly raise (P<0.01), and metformin group, 1 group of embodiment, 2 groups of embodiment, 3 groups of glycolated hemoglobin levels of embodiment obviously reduce (P<0.05 or P<0.01) compared with model group.Result shows that the present invention has the effect of remarkable reduction rat model of type 2 diabetes mellitus blood glucose and glycolated hemoglobin.
The impact of table 1 the present invention on rat model of type 2 diabetes mellitus fasting glucose and glycolated hemoglobin (
)
Note: with Normal group ratio
*p<0.01; With model group ratio
△p <0.05,
△ △p<0.01.
2) fasting blood glucose level can antimer in the basic carbohydrate metabolism situation of a time point, a glycometabolic average level of time period in the main antimer of glycolated hemoglobin.Conventionally diagnose and treat diabetes by these two indexs clinically.Result of the test shows, the present invention has the effect of remarkable reduction rat model of type 2 diabetes mellitus fasting glucose, glycolated hemoglobin.The present invention is the compound Chinese patent medicine summing up in clinical practice for many years, aspect improvement 2 phase diabetes clinical symptoms, reduction blood glucose, is having good effect.
The impact of embodiment 7 the present invention on diabetic nephropathy model rat
Diabetic nephropathy (DN) is one of microvascular complication of diabetes, is the important death cause of diabetics.The principal character of DN is that urine protein increases and glomerular sclerosis, and the pathological change of observing albuminuria and kidney can reflect the Renoprotective Effect of medicine.
1, materials and methods
1) 1. animal of experiment material: 60 of SPF level male rats, body weight 250 ~ 280g, is provided by Wuhan University pharmacological evaluation chamber.2. medicine and reagent: lotensin sheet is provided by Novartis Co.,Ltd, streptozotocin (STZ) is provided by Sigma company of the U.S..
2) DN rat model copy 60 of SPF level SD male rats, freely drink water and take food 3 days to conform.Choose at random 10 of blank groups by body weight and upgrowth situation, all the other fasting be can't help water 24 hours, lumbar injection STZ solution (dosage 45mg/Kg), inject after 72 hours, fasting be can't help water 6 hours, tail venous blood sampling is surveyed blood glucose, gets the rat continuation modeling of blood glucose (BG) value >=16.8mmol/L, raise with the next day high lipid food; The aseptic citric acid-sodium citrate buffer of lumbar injection Isodose under blank group equal conditions, raises with normal diet.Tail vein blood survey at 4 weekends blood glucose, metabolic cage method is surveyed twenty-four-hour urine protein quantification, fasting glucose (BG) value >=16.8mmol/L, twenty-four-hour urine protein quantification >=20mg/24h is judged to be DN rat modeling success simultaneously.
3) grouping and intervene that to have 32 rats up to standard.Be divided at random 11 of model group, 10 of lotensin groups, 11 of medicine groups of the present invention.After grouping, start to intervene totally 6 weeks.Blank group gives normal diet, other each group high lipid food give the next day, ad lib water.The dosage of rat is according to admitting that conventional dose and human body and rat body surface area convert.Blank group and model group give 0.9% sodium chloride injection 10ml/Kg/ days gavage; Lotensin group gives lotensin 2mg/Kg/ days gavage; Press 6g crude drug/Kg/ days gavage for of the present invention group.In intervention, tail venous blood sampling is surveyed blood glucose 1 time weekly, and BG value <16.8mmol/L person eliminated.
4) observation index and detection method administration metabolic cage method at the 6th weekend are collected each group of rat urine, and toluene is anticorrosion, and automatic clinical chemistry analyzer detects 24h urine protein quantitation.Fasting in morning next day be can't help giving 10% chloral hydrate anesthesia (3ml/Kg) after water 5h, heart extracting blood, and automatic clinical chemistry analyzer detects BG, blood urea nitrogen (BUN), serum creatinine (SCr), T-CHOL (TCh), triglyceride (TG).
5) Application of Statistic Methods SPSS13.0 statistical software.Dosage data with (
) represent, adopt one factor analysis of variance.
2, result
1) respectively organize DN rat blood sugar, renal function changes relatively in table 2.Result shows that of the present invention group of blood urea nitrogen all reduces compared with model group, lotensin group; Difference has statistical significance (P<0.01 or 0.05); Serum creatinine difference not statistically significant (P>0.05) between four groups of blank, the present invention, lotensin, model.
The each group of table 2 Dn Renal Function in Rats variation comparison (
)
With the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison,
△p<0.05,
△ △p<0.01; With the comparison of lotensin group,
#p<0.05,
##p<0.01.
2) respectively organize DN rat protein urine, Blood Lipid relatively in table 3.Result shows the present invention, lotensin, more blank group of rising of three groups of 24h urine protein quantitation of model; 24h urine protein quantitation of the present invention reduces compared with model group; All more blank group of risings of the present invention, lotensin, model three groups of TCh, TG; Of the present invention group of TCh, TG all have reduction compared with model group and lotensin group; Difference has statistical significance (P<0.01 or 0.05).
The each group of table 3 DN rat protein urine, Blood Lipid comparison (
)
With the comparison of blank group,
*p<0.05,
*p<0.01; With model group comparison,
△p<0.05,
△ △p<0.01; With the comparison of lotensin group,
#p<0.05,
##p<0.01.
3) the present invention is taking benefiting QI for activating blood circulation yin nourishing as the principles of formulating prescriptions; can find out from the above results; the present invention has the effect that reduces experimental DN rat protein urine; of the present invention group of TCh, TG all have reduction (P<0.01 or 0.05) compared with lotensin, model group simultaneously; therefore the present invention has the effect that regulates experimental DN lipid metabolism in rats; and this effect is better than lotensin, prompting the present invention has the effect of protection kidney.
The clinical research of embodiment 8 the present invention to 2 phase diabeticss
Treat 2 phase 30 patients with diabetes mellitus with the present invention, and treat 30 examples as contrast taking metformin hydrochloride, result is as follows:
1, materials and methods
1) 60 routine patients are divided into treatment group 30 example and matched group 30 examples by physical data, and two groups of ages, sex, the course of disease, body weight, fasting glucose (FBG) 2 hours blood glucoses after the meal early, learn processing difference not obvious by statistics, have comparability.
2) diagnostic criteria fasting glucose >=7.0mmol/L(or random blood sugar >=11.1mmol/L), or oral glucose tolerance test 2h blood glucose >=11.1mmol/L.
3) treatment and observational technique
1. Therapeutic Method all patients is stopped using, and all have the medicine of blood sugar lowering, effect for reducing blood fat.Keeping on a diet, on motion and diabetes education basis, matched group gives metformin hydrochloride tablet 0.5g, and every day 2 times is oral; Treatment group is given medicine of the present invention, and every day three times is oral, and each 3 (capsules), 2 groups all taking 4 weeks as 1 course for the treatment of, treats altogether 3 courses for the treatment of.
2. observation index clinical symptoms integration, FBG, glycolated hemoglobin (HbAlc), T-CHOL (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C).
3. statistical method measurement data adopts t inspection, and enumeration data adopts x
2inspection.
4) criterion of therapeutical effect in curative effect determinate standard reference " new Chinese medicine is studied guideline when participating in the cintest ": effective: symptom integral reduces >=70%, FBG is normal or decline more than 40%, HbAlc is normal or decline more than 30%, and the improvement of TC, TG, LDL-C is more than 30% or recover normal; Effective: it is normal or decline more than 20% that symptom integral reduces by >=30%, FBG, HbAlc is normal or decline more than 10%, and TC, TG, LDL-C make moderate progress before treating, but not enough effective standard; Invalid: clinical symptoms thing change or increase the weight of or less than 30%, lab index unchanged or raise.
2, result
1) effective 12 examples of effective rates group, effective 11 examples, invalid 7 examples, total effective rate 76.6%.Effective 14 examples of matched group, effective 8 examples, invalid 8 examples, total effective rate 73.3%.2 groups of total effective rate comparisons, there was no significant difference, points out both curative effect close.
2) before and after 2 groups of treatments of clinical symptoms integration, clinical symptoms integration improves situation relatively in table 4.Before and after treatment, compare, treatment group has utmost point significant difference (P<0.01), matched group compares after having the treatment of statistical significance (P<0.05) .2 group, have significant difference (P<0.01), prompting the present invention is being better than Western medicine aspect the clinical symptoms of improvement 2 phase diabetes.
Clinical symptoms integration improvement situation comparison before and after 2 groups of treatments of table 4 (
)
| Group | Number of cases | Before treatment | After treatment |
| Matched group | 30 | 16.5±3.15 | 12.2±2.22 * |
| Treatment group | 30 | 16.8±3.07 | 8.3±2.68 **△ |
Note: relatively front with treatment,
*p<0.05,
*p<0.0,1; With comparison after treatment of control group
△p<0.01
3) before and after 2 groups of treatments of carbohydrate metabolism, FBG, HbAlc change relatively in table 5.After 2 groups of treatments, all can obviously reduce FBG and HbAlc, difference has significance (P<0.01), but 2 groups are compared without significant difference.It is suitable with metformin hydrochloride that prompting the present invention improves glycometabolic effect.
FBG, HbAlc variation comparison before and after 2 groups of treatments of table 5 (
)
Note: relatively front with treatment,
*p<0.01
4) 2 groups for the treatment of front and back Blood Lipid of blood lipid metabolism are relatively in table 6.Before and after treatment group treatment, compare, by significant difference (P<0.01), matched group difference thing significant (P>0.05).After treatment, treatment group is compared with matched group, has significant difference (P<0.01), shows that the present invention has the lipometabolic effect of good adjusting, is better than metformin hydrochloride tablet.
Lipid metabolism variation comparison before and after 2 groups of treatments of table 6 (
, mmol/L)
Note: relatively front with treatment,
*p<0.01; With comparison after treatment of control group
△p<0.01.
Claims (3)
1. a Chinese medicine for the treatment of diabetes and diabetic nephropathy, is characterized in that: described Chinese medicine is made up of the raw material of following weight proportioning:
10～40 parts of 30～60 parts of Ramulus Moris of 50～100 parts of Herba Spirodelae grass of 50～100 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
10～40 parts of 20～50 portions of Fructus Crataegis of 20～50 parts of Radix Puerariaes of Semen Coicis.
2. the Chinese medicine for the treatment of diabetes according to claim 1 and diabetic nephropathy, is characterized in that: the weight proportion of described raw material is:
20～30 parts of 40～50 parts of Ramulus Moris of 60～80 parts of Herba Spirodelae grass of 60～80 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
20～30 parts of 30～40 portions of Fructus Crataegis of 30～40 parts of Radix Puerariaes of Semen Coicis.
3. the Chinese medicine for the treatment of diabetes according to claim 1 and diabetic nephropathy, is characterized in that: the weight proportion of described raw material is:
25 parts of 45 parts of Ramulus Moris of 70 parts of Herba Spirodelae grass of 70 parts of Radixs Astragali of Radix Salviae Miltiorrhizae
25 parts of 35 portions of Fructus Crataegis of 35 parts of Radix Puerariaes of Semen Coicis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310163090.1A CN103230552B (en) | 2013-05-06 | 2013-05-06 | Traditional Chinese medicine for treating diabetes mellitus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310163090.1A CN103230552B (en) | 2013-05-06 | 2013-05-06 | Traditional Chinese medicine for treating diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103230552A CN103230552A (en) | 2013-08-07 |
| CN103230552B true CN103230552B (en) | 2014-08-27 |
Family
ID=48878667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310163090.1A Expired - Fee Related CN103230552B (en) | 2013-05-06 | 2013-05-06 | Traditional Chinese medicine for treating diabetes mellitus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103230552B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104857025A (en) * | 2015-05-28 | 2015-08-26 | 徐忠兰 | Therapeutic method by utilizing medicines to cure diabetics |
| CN105213525A (en) * | 2015-10-28 | 2016-01-06 | 葛善文 | A kind of Chinese medicine preparation for the treatment of diabetes and its production and use |
-
2013
- 2013-05-06 CN CN201310163090.1A patent/CN103230552B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| 中医药治疗2型糖尿病的研究进展;朱志远等;《四川中医》;20111231;第29卷(第5期);48-52 * |
| 朱志远等.中医药治疗2型糖尿病的研究进展.《四川中医》.2011,第29卷(第5期),48-52. |
| 糖尿病肾病的中西医护理;莫才英等;《辽宁中医杂志》;20121231;第39卷(第3期);542-544 * |
| 莫才英等.糖尿病肾病的中西医护理.《辽宁中医杂志》.2012,第39卷(第3期),542-544. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103230552A (en) | 2013-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101708295B (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN103566350B (en) | A kind of pharmaceutical composition with hypoglycemic effect | |
| CN100493572C (en) | Composition of medication for treating diabetes | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN101856405B (en) | A kind of pharmaceutical composition for treating type 2 diabetes and its preparation method | |
| CN102813870B (en) | Chinese herbal compound preparation used for treating alcoholism and gout and preparation method and application thereof | |
| CN116870095A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN1321671C (en) | Chinese medicinal composition, its preparation method and use | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN100389804C (en) | 'Qimailing' oral liquid and its preparation method | |
| CN102631595A (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102488838A (en) | Traditional Chinese medicine composition used for treating viral myocarditis | |
| CN103432420B (en) | A kind of Chinese medicine composition for the treatment of diabetes and preparation method thereof and detection method | |
| CN102293855A (en) | Chinese medicinal composition for treating speech and kidney deficiency diabetic nephropathy, and preparation method and application thereof | |
| CN102018852A (en) | Ginseng and coptis capsule for quenching thirsty and reducing blood sugar and preparation process | |
| CN109806339A (en) | A kind of preparation and preparation method thereof improving endocrine integration of drinking and medicinal herbs | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN104491416B (en) | A kind of Chinese medicine composition for being used to treat diabetes | |
| CN119896709B (en) | A traditional Chinese medicine composition for diabetic nephropathy, its preparation method and application | |
| CN115645493B (en) | Traditional Chinese medicine preparation for treating chronic kidney disease stage 3 and preparation method thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN103877374B (en) | A kind of for Chinese medicine treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140827 Termination date: 20150506 |
|
| EXPY | Termination of patent right or utility model |